Durham, NCNCT05491525Now EnrollingIRB Ready

Overactive Bladder Clinical Trial in Durham, NC

Access cutting-edge overactive bladder treatment through this phase 2/3 clinical trial at a research site in Durham. Study-provided care at no cost to qualified participants.

Sponsored by Urovant Sciences GmbH

Quick Self-Assessment

See if you qualify for this Durham location

Preparing your pre-screening questions…

Expert Care in Durham

Access overactive bladder specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related overactive bladder treatment provided free

Apply for This Durham Location

Check if you qualify for this overactive bladder clinical trial in Durham, NC

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Durham

    Convenient for NC residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Durham site if eligible
  4. 4Begin participation

About This Overactive Bladder Study in Durham

The purpose of this study is to evaluate the safety, efficacy, and PK of vibegron in pediatric participants with NDO who are regularly using CIC

Sponsor: Urovant Sciences GmbH

Who Can Participate

Inclusion Criteria

Male or female participants, age 2 years to \< 18 years and weighing at least 11 kg at the Screening Visit.
Participant has been diagnosed with NDO due to one of the following: spinal dysraphism, which includes spina bifida (eg, myelomeningocele, meningocele) and all forms of tethered cord; or acquired NDO from a spinal cord injury or spinal cord surgery, with the injury/surgery having occurred at least 6 months prior to the Screening Visit; or acquired NDO due to transverse myelitis with diagnosis at least 12 months prior to the Screening Visit.
Participant undergoes CIC at least 3 times per 24 hours (with the last CIC performed prior to going to sleep for the night) for at least 4 weeks prior to the Screening Visit.

Exclusion Criteria

Participant has cerebral palsy, uncontrolled epilepsy, diabetes insipidus, or Stage 2 hypertension
Participant has an active malignancy in the 12 months prior to the Screening Visit.
Participant has been administered intravesical botulinum toxin within 9 months prior to the Screening Visit and should remain off this therapy during the study.
Participant is taking digoxin or lithium within 10 days prior to Screening Visit or plans to start taking either during the study.
Participant currently uses or plans to use a baclofen pump during the study.
Participant has had urethral dilatation or urethral surgery in the 3 months prior to the Screening Visit.
Participant has undergone bladder augmentation surgery.
Participant has a known genitourinary condition (other than NDO) that may cause overactive contractions or incontinence (bladder exstrophy, urinary tract obstruction, urethral diverticulum or fistula) or bladder stones or another persistent urinary tract pathology that may cause symptoms.
Participant has an insufficient urethral sphincter, has had implantation of an artificial sphincter, has a surgically-treated underactive urethral sphincter, or, in the 6 months prior to the Screening Visit, has undergone pelvic gender reassignment surgery.
Participant has one of the following gastrointestinal problems: partial or complete obstruction, decreased motility such as paralytic ileus, risk of gastric retention, or malabsorption syndrome of any form.
Participant has acute fecal impaction or, within the 3 months prior to the Screening Visit, had fecal impaction that required hospitalization or ambulatory surgical treatment.
Participant had a urinary indwelling catheter in the 4 weeks prior to the Screening Visit.
Participant has moderate to severe dilating vesicoureteral reflux (Grade IV to V) or severe renal failure.
Participant started electrostimulation/neuromodulation therapy in the 4 weeks before the Screening Visit, or is expected to start this therapy during the study period.
Participant has participated in another clinical trial and/or has taken an investigational drug within 4 weeks prior to the Screening Visit.
Participant is unable, or parent/caregiver is not willing, to washout any medication for the management of NDO.
Participant is a female of childbearing potential who is unwilling or unable to use a highly effective method of contraception for the duration of the study.
Female participants who are currently breastfeeding or plan to breastfeed any time from the Screening Visit until 28 days after the final study drug administration.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Durham?

Yes, this clinical trial (NCT05491525) has an active research site in Durham, NC that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Overactive Bladder Treatment Options in Durham, NC

If you're searching for overactive bladder treatment options in Durham, NC, this clinical trial (NCT05491525) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Durham research site is actively enrolling participants for this phase 2/3 clinical trial. You'll receive care from experienced overactive bladder specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all overactive bladder clinical trials near you to find additional studies recruiting in your area.

More Alzheimers Disease Trials in Durham, NC

See all alzheimers disease clinical trials recruiting in Durham — not just this study.

Browse Alzheimers Disease Trials in Durham →

Browse More Trials by Condition

Alzheimers Disease TrialsADHD TrialsRheumatoid Arthritis TrialsAtopic Dermatitis TrialsOveractive Bladder TrialsAll Conditions →

Ready to Join in Durham?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Durham, NC